1. Switzerland Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - General
Roche Holding AG

Roche Holding AG

RHHBY
Roche Holding AGUS flagOther OTC
51.65
USD
+0.30
- -
332.67BMarket Cap
Roche Holding AG
RHHBY
(Other OTC)

Recent

price

51.65

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
FRC
6.94
6.26
6.71
6.9
6.99
7.07
7.42
7.81
8.32
8.98
8.53
9.24
10.28
9.46
9.79
9.95
Revenue per Share
1.27
1.38
1.39
1.65
1.37
1.3
1.4
1.27
1.54
1.97
2.09
2.05
1.94
1.8
1.3
2.02
Basic EPS, GAAP
1.66
1.58
1.86
1.9
1.85
1.64
1.45
2.02
2.2
2.55
1.74
2.42
2.07
1.79
2.37
2.05
Free Cash Flow per Basic Share
0.77
0.85
0.87
0.94
0.99
1.02
1.03
1.05
1.06
1.09
1.13
1.14
1.16
1.19
1.2
1.21
Dividend per Share
2.15
2.57
2.98
3.8
3.87
4.22
4.59
4.9
5.14
5.94
6.69
5.05
6.1
6.64
6.89
7.69
Book Value per Share
-0.17
0.23
0.75
1.5
-0.17
-0.24
0.45
1.55
1.77
2.16
2.71
0.8
1.8
1.42
1.72
1.74
Tangible Book Value per Share
6,840
6,792
6,784
6,784
6,792
6,808
6,816
6,824
6,832
6,848
6,840
6,800
6,400
6,392
6,376
6,368
Basic Weighted Avg Shares
47,473
42,531
45,499
46,780
47,462
48,145
50,576
53,299
56,846
61,466
58,323
62,801
65,814
60,441
62,395
63,356
Sales/Revenue/Turnover
28.37
31.6
31.04
35.01
29.69
28.71
27.82
24.4
25.98
28.55
31.79
28.91
26.55
25.47
21.5
29.16
Operating Margin (%)
2,552
2,368
2,421
2,381
2,623
3,640
3,941
3,887
3,586
4,292
4,558
4,443
3,844
3,464
3,423
3,386
Depreciation Expense
8,666
9,343
9,427
11,164
9,332
8,863
9,576
8,633
10,500
13,497
14,295
13,930
12,421
11,498
8,277
12,880
Net Income, GAAP
20.69
19.7
20.55
22.51
23.81
24.45
25.17
27.95
23.2
15.08
16.13
14.16
17.13
12.22
22.1
18.7
Effective Tax Rate (%)
18.25
21.97
20.72
23.86
19.66
18.41
18.93
16.2
18.47
21.96
24.51
22.18
18.87
19.02
13.27
20.33
Profit Margin (%)
12,634
12,022
11,162
13,404
8,006
4,414
6,070
9,412
9,211
7,135
7,541
-2,789
6,577
8,622
13,013
10,728
Working Capital
27,857
23,459
17,860
16,423
19,347
17,100
16,992
15,839
16,077
13,547
11,096
17,101
22,282
26,092
32,097
28,674
LT Debt
11,662
14,506
16,750
21,241
21,558
23,300
26,402
29,007
30,366
35,867
39,773
28,345
32,015
33,263
36,161
37,880
Total Equity
21.75
24.73
25.81
29.84
23.5
21.12
20.95
18.26
21.79
27.59
27.28
25.4
23.07
21.1
14.73
20.08
Return on Invested Capital (%)
20.17
23.02
22.44
25.66
19.97
17.56
18.36
16.19
19.23
23.38
22.57
19.64
16.93
15.69
10.45
15.28
Return on Capital (%)
64.9
58.11
50.08
48.53
35.81
32.19
31.92
26.7
30.65
35.62
33.08
34.8
33.86
28.22
19.16
27.73
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
5.85%
0.32%
4.75%
Free Cash Flow
4.55%
4.76%
-13.34%
Net Income, GAAP
6.11%
1.36%
55.61%
Sales/Revenue/Turnover
2.92%
1.82%
1.54%
Total Cash Common Dividend
1.08%
0.1%
1.06%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
60,441
2024
- -
- -
- -
- -
62,395
2025
- -
- -
- -
- -
63,356

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
1.8
2024
- -
- -
- -
- -
1.3
2025
- -
- -
- -
- -
2.02

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
1.19
2024
- -
- -
- -
- -
1.2
2025
- -
- -
- -
- -
1.21
Similar Companies
Chugai Pharmaceutical Co., Ltd. (CHGCY)
Fangzhou Inc. (6086.HK)
PT Kalbe Farma Tbk. (KLBF.JK)
CSPC Pharmaceutical Group Limited (1093.HK)
JCR Pharmaceuticals Co., Ltd. (4552.T)
GSK plc (GSK.L)
Business
Roche Holding AG, headquartered in Basel, Switzerland and founded in 1896, operates as one of the world's largest biotechnology companies and the global leader in in-vitro diagnostics; it develops and markets innovative medicines and diagnostic products across oncology, immunology, infectious diseases, ophthalmology, neuroscience, hematology, respiratory diseases, cardiovascular, renal and metabolic disorders, rare diseases, and women's health, with key pharmaceutical brands including Avastin, MabThera/Rituxan, Herceptin, Perjeta, Tecentriq, Hemlibra, Ocrevus, and Vabysmo; its diagnostics portfolio encompasses in-vitro diagnostics, point-of-care testing such as the recently FDA-cleared CLIA-waived test for Bordetella infections including whooping cough, continuous glucose monitoring systems, cell analysis, gene expression, genome sequencing, and nucleic acid purification technologies; the company serves customers worldwide through operations in more than 130 countries, with significant presence via wholly-owned Genentech in the United States and majority stake in Japan's Chugai Pharmaceutical. Roche maintains two primary segments, Pharmaceuticals and Diagnostics, targeting healthcare providers, researchers, and patients with personalized healthcare solutions that integrate data insights from clinical practice. Recent developments include a definitive merger agreement in September 2025 to acquire 89bio for up to $3.5 billion to bolster its cardiovascular, renal, and metabolic portfolio with pegozafermin for moderate to severe MASH; a $50 billion investment commitment over five years announced in April 2025 to expand U.S. R&D and manufacturing in states including Indiana, Pennsylvania, Massachusetts, and California, creating over 12,000 jobs; a $550 million expansion of its Indianapolis diagnostics site for continuous glucose monitoring by 2030; prior acquisitions such as Carmot Therapeutics in 2024, Televant Holdings for $7.1 billion in 2023, and partnerships like those with Innovent Biologics and Poseida Therapeutics; and 53 new collaboration agreements in 2024 alongside ongoing M&A firepower of about $10 billion annually.

Company News

MCPAPIChat

  • globenewswire.com

    Roche receives FDA approval for the first companion diagnostic to assess PTEN protein in people living with prostate cancer

  • zacks.com

    Roche's Tecentriq Plus Chemo Gets FDA Priority Tag for Colon Cancer

  • seekingalpha.com

    Nurix Therapeutics Deal With Roche Is Worth Betting On

  • seekingalpha.com

    Roche Vs. Pfizer: Obesity Week Presentations Deep Dive - What Investors Must Know

  • seekingalpha.com

    Nurix Therapeutics: 'Strong Buy' Due To Roche Deal And Bexobrutideg Expansions

  • reuters.com

    Roche sticks to German investment after Eli Lilly cuts

  • seekingalpha.com

    Roche Holding AG (RHHBY) Shareholder/Analyst Call Transcript

  • gurufocus.com

    Roche's $2.3 Billion Nurix Deal Sends Shares Moving

  • zacks.com

    Roche, Nurix Team Up to Advance BTK Degrader Bexobrutideg

  • zacks.com

    BAYRY or RHHBY: Which Is the Better Value Stock Right Now?

  • barrons.com

    This Biotech Stock Is Up 11% on $2.3 Billion Roche Deal for Blood Cancer Drug

  • investors.com

    Roche Inks $2.3 Billion Deal, Sending This Small Biotech Stock Flying

  • schaeffersresearch.com

    Nurix Therapeutics Stock Pops on Roche Partnership

  • benzinga.com

    Nurix Therapeutics Gains Ground As Roche Partnership Targets Growing B-Cell Blood Cancer Market

  • reuters.com

    Roche enters $2 billion cancer drug agreement with Nurix Therapeutics

  • wsj.com

    Roche Enters $2.3 Billion Blood-Cancer Drug Deal With Nurix Therapeutics

  • globenewswire.com

    Roche announces global collaboration with Nurix Therapeutics to co-develop and co-commercialise potential best-in-class BTK degrader bexobrutideg across malignant haematology, immunology and neurology

  • globenewswire.com

    Nurix Therapeutics Announces Global Collaboration with Roche to Co-Develop and Co-Commercialize Potential Best-in-Class BTK Degrader Bexobrutideg Across Malignant Hematology, Immunology and Neurology

  • reuters.com

    Roche obesity drug helps patients shed 22.7% of weight in mid-stage trial

  • reuters.com

    Zealand touts promising tolerability data for obesity drug in mid-stage study